What’s Ahead for Sangamo Therapeutics, Inc. (SGMO) After Today’s Huge Increase?

December 7, 2017 - By Marie Mckinney

Investors sentiment increased to 1.59 in Q2 2017. Its up 0.79, from 0.8 in 2017Q1. It improved, as 13 investors sold Sangamo Therapeutics, Inc. shares while 31 reduced holdings. 33 funds opened positions while 37 raised stakes. 50.83 million shares or 24.82% more from 40.72 million shares in 2017Q1 were reported.
Panagora Asset Management owns 2,693 shares. Sanctuary Wealth Advsr Ltd Liability holds 1,001 shares or 0.01% of its portfolio. First Mercantile Trust has 4,687 shares for 0.01% of their portfolio. Invesco holds 0% or 54,507 shares in its portfolio. Moreover, Group Inc Inc has 0% invested in Sangamo Therapeutics, Inc. (NASDAQ:SGMO) for 44,268 shares. Balyasny Asset Llc has 351,700 shares. Schwab Charles Investment Inc reported 0% in Sangamo Therapeutics, Inc. (NASDAQ:SGMO). Art Lc has 29,146 shares for 0.01% of their portfolio. Iguana Healthcare Limited Liability Company owns 215,000 shares. Hightower Advsrs Lc holds 29,405 shares or 0% of its portfolio. Pub Employees Retirement Association Of Colorado has invested 0% in Sangamo Therapeutics, Inc. (NASDAQ:SGMO). 235,958 were accumulated by Gp One Trading Ltd Partnership. Pub Employees Retirement System Of Ohio invested 0.01% of its portfolio in Sangamo Therapeutics, Inc. (NASDAQ:SGMO). Wells Fargo Commerce Mn owns 0% invested in Sangamo Therapeutics, Inc. (NASDAQ:SGMO) for 431,234 shares. 34,008 are held by Barclays Public Limited Co.

The stock of Sangamo Therapeutics, Inc. (NASDAQ:SGMO) is a huge mover today! The stock increased 5.20% or $0.85 during the last trading session, reaching $17.2. About 1.37M shares traded. Sangamo Therapeutics, Inc. (NASDAQ:SGMO) has risen 29.78% since December 7, 2016 and is uptrending. It has outperformed by 13.08% the S&P500.
The move comes after 8 months positive chart setup for the $1.45B company. It was reported on Dec, 7 by Barchart.com. We have $18.06 PT which if reached, will make NASDAQ:SGMO worth $72.70M more.

Analysts await Sangamo Therapeutics, Inc. (NASDAQ:SGMO) to report earnings on February, 27. They expect $-0.23 earnings per share, down 64.29 % or $0.09 from last year’s $-0.14 per share. After $-0.15 actual earnings per share reported by Sangamo Therapeutics, Inc. for the previous quarter, Wall Street now forecasts 53.33 % negative EPS growth.

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Ratings Coverage

Among 10 analysts covering Sangamo Biosciences (NASDAQ:SGMO), 6 have Buy rating, 1 Sell and 3 Hold. Therefore 60% are positive. Sangamo Biosciences had 21 analyst reports since August 8, 2015 according to SRatingsIntel. The firm has “Neutral” rating given on Wednesday, October 19 by Piper Jaffray. Jefferies maintained Sangamo Therapeutics, Inc. (NASDAQ:SGMO) on Tuesday, September 12 with “Buy” rating. The stock of Sangamo Therapeutics, Inc. (NASDAQ:SGMO) earned “Buy” rating by JP Morgan on Thursday, September 3. Wedbush maintained Sangamo Therapeutics, Inc. (NASDAQ:SGMO) rating on Wednesday, November 15. Wedbush has “Hold” rating and $6.0 target. On Wednesday, November 15 the stock rating was upgraded by PiperJaffray to “Overweight”. The company was maintained on Wednesday, September 2 by Wedbush. Wedbush downgraded it to “Neutral” rating and $4 target in Tuesday, November 1 report. The stock of Sangamo Therapeutics, Inc. (NASDAQ:SGMO) earned “Hold” rating by Piper Jaffray on Thursday, August 10. The stock of Sangamo Therapeutics, Inc. (NASDAQ:SGMO) has “Buy” rating given on Thursday, June 22 by Jefferies. JP Morgan maintained Sangamo Therapeutics, Inc. (NASDAQ:SGMO) on Saturday, August 8 with “Overweight” rating.

More notable recent Sangamo Therapeutics, Inc. (NASDAQ:SGMO) news were published by: Seekingalpha.com which released: “Sangamo Therapeutics: Engineering Genomic Solutions For Rare Diseases” on December 07, 2017, also Nasdaq.com with their article: “Commit To Buy Sangamo Therapeutics At $8, Earn 21.9% Using Options” published on November 08, 2017, Prnewswire.com published: “Sangamo Announces Strategic Investment In Manufacturing And Appointment Of …” on November 09, 2017. More interesting news about Sangamo Therapeutics, Inc. (NASDAQ:SGMO) were released by: Nasdaq.com and their article: “Sangamo Therapeutics (SGMO) in Focus: Stock Moves 13.6% Higher” published on November 16, 2017 as well as Seekingalpha.com‘s news article titled: “Sangamo’s Powerful Pipeline Drives Significant Upside” with publication date: November 17, 2017.

Sangamo Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on translating ground-breaking science into genomic therapies that transform patients' lives using platform technologies in genome editing, gene therapy, gene regulation, and cell therapy. The company has market cap of $1.45 billion. The companyÂ’s proprietary zinc finger DNA-binding protein technology enables specific genome editing and gene regulation. It currently has negative earnings. The ZFPs could be engineered to make ZFP nucleases (ZFNs), proteins that could be used to specifically modify DNA sequences by adding or knocking out specific genes; and ZFP transcription factors (ZFP TFs), proteins that can be used to turn genes on or off.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.